Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Altered Innate Immunity Confers Staphylococcus aureus Resistance in O-glycosylation Deficient Caenorhabditis elegans bus Mutants

ABSTRACT: Altered Innate Immunity Confers Staphylococcus aureus Resistance in O-glycosylation Deficient Caenorhabditis elegans bus Mutants

PROVIDER: PRJNA601206 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Altered Innate Immunity Confers Staphylococcus aureus Resistance in O-glycosylation Deficient Caenorhabditis elegans bus Mutants

Project description:The Caenorhabditis elegans bus (bacterial unswollen) mutants were isolated by their altered response to the nematode pathogen Microbacterium nematophilum. The bus-2, bus-4 and bus-17 mutants are resistant to infection by this bacterium and to infection by human pathogens Yersinia pestis and Yersinia pseudotuberculosis. Here we extend that list to Staphylococcus aureus. The bus-2, bus-4 and bus-17 mutants each harbors a defect in a different glycosyltransferase involved in O-glycosylation. Glycomics analysis of these strains reveals significant O-glycosylation defects. We further investigated the nature of bus mutant phenotypes in bus-2, bus-4 and bus-17 by gene expression analysis. Three distinct areas of altered expression were identified: 1) N- and O-glycosylation; 2) innate immune response; 3) protein folding and editing control. As expected N- and O-glycosylation gene expression was altered at key enzymatic steps. Innate immune system expression patterns were altered in a way that significantly overlapped with expression patterns seen in wild-type upon exposure to Staphylococuss aureus. Upon infection with S. aureus markers of innate immune activity increased significantly compared to wild-type. The abu/pqn genes, active in the non-canonical unfolded protein response (UPR) pathway were dramatically upregulated in bus when these mutants were exposed to the pathogen. This work demonstrates a genetic link between O-glycosylation and expression of key components of the innate immune response.

2021-01-06 | GSE143664 | GEO

Hobit confers tissue dependent programs to type 1 innate lymphoid cells

Project description:Hobit confers tissue dependent programs to type 1 innate lymphoid cells

| PRJNA768803 | ENA

Multilevel Plasticity and Altered Glycosylation Drive Aggressiveness in Hypoxic and Glucose-Deprived Bladder Cancer Cells

Project description:Bladder tumours with aggressive characteristics often present microenvironmental niches marked by low oxygen levels (hypoxia) and limited glucose supply due to inadequate vascularization. The molecular mechanisms facilitating cellular adaptation to these stimuli remain largely elusive. Employing a multi-omics approach, we discovered that hypoxic and glucose-deprived cancer cells enter a quiescent state supported by mitophagy, fatty acid β-oxidation, and amino acid catabolism, concurrently enhancing their invasive capabilities. Reoxygenation and glucose restoration efficiently reversed cell quiescence without affecting cellular viability, highlighting significant molecular plasticity in adapting to microenvironmental challenges. Furthermore, cancer cells exhibited substantial perturbation of protein O-glycosylation, leading to simplified glycophenotypes with shorter glycosidic chains. Exploiting glycoengineered cell models, we established that immature glycosylation contributes to reduced cell proliferation and increased invasion. Our findings collectively indicate that hypoxia and glucose deprivation trigger cancer aggressiveness, reflecting an adaptive escape mechanism underpinned by altered metabolism and protein glycosylation, providing grounds for clinical intervention.

2025-02-12 | GSE284635 | GEO

Altered RNA export by SF3B1 mutants confers sensitivity to nuclear export inhibition

Project description:Altered RNA export by SF3B1 mutants confers sensitivity to nuclear export inhibition

| PRJNA1073893 | ENA

Transposon-triggered innate immune response confers cancer resistance to the blind mole rat

Project description:Transposon-triggered innate immune response confers cancer resistance to the blind mole rat

| PRJNA753121 | ENA

O-GlcNAcylation Modulates Expression and Abundance of N-Glycosylation Machinery in an Inherited Glycosylation Disorder

Project description:Much of the N-glycosylation machinery was identified decades ago, but the regulatory mechanisms influencing normal and disease states are only beginning to be discovered. Recent studies highlight a role for key metabolites and metabolic enzymes in this process, revising the view of the relationship between different metabolic pathways. Using a multi-omic approach in a zebrafish, we discovered a mechanism where O-GlcNAcylation directly influences the expression and abundance of two enzymes essential for the earliest steps of N-linked glycosylation, the nus1-encoded NgBR and Dpagt1. Here we show that phosphomannomutase (pmm2) deficiency is associated with increased levels of UDP-GlcNAc and protein O-GlcNAcylation. Biochemical studies show that O-GlcNAc modification of the NgBR and Dpagt1 increases their abundance in pmm2m/m mutants. Modulating O-GlcNAc levels, NgBR abundance or Dpagt1 activity exacerbated cartilage phenotypes in pmm2 mutants, suggesting that O-GlcNAc mediated increases in the N-glycosylation machinery protects against more severe pathology. These findings highlight nucleotide-sugar donors as metabolic sensors that coordinate two different glycosylation pathways, demonstrating how their interplay is relevant to disease outcome in the most common congenital disorder of glycosylation.

2024-12-27 | GSE269074 | GEO

Pilot project to determine optimal bioreactor protein glycosylation conditions

Project description:These research areas concentrate on stress induced proteases in recombinant Escherichia coli, glycosylation heterogeneity due to bioprocess conditions produced in mammalian cells, and metabolic engineering of E. coli. The hypothesis of this project is that recombinant protein glycosylation is inefficient under normal bioreactor conditions since the additional glycosylation reactions necessary for the recombinant protein exceed the metabolic capacity of the cells. Normal bioreactor conditions have been optimized for cell growth, and sometimes for protein productivity. Only recently has it been accepted that optimal glycosylation may not occur under optimal growth or protein productivity conditions. Specific Aim: Determine the relationship between bioreactor conditions and glycosylation gene expression in NS0 cells.

2011-04-29 | GSE28920 | GEO

Altered RNA export by SF3B1 mutants confers sensitivity to nuclear export inhibition.

Project description:SF3B1 mutations frequently occur in cancer yet lack targeted therapies. Clinical trials of XPO1 inhibitors, selinexor and eltanexor, in high-risk myelodysplastic neoplasms (MDS) revealed responders were enriched with SF3B1 mutations. Given that XPO1 (Exportin-1) is a nuclear exporter responsible for the export of proteins and multiple RNA species, this led to the hypothesis that SF3B1-mutant cells are sensitive to XPO1 inhibition, potentially due to altered splicing. Subsequent RNA sequencing after XPO1 inhibition in SF3B1 wildtype and mutant cells showed increased nuclear retention of RNA transcripts and increased alternative splicing in the SF3B1 mutant cells particularly of genes that impact apoptotic pathways. To identify novel drug combinations that synergize with XPO1 inhibition, a forward genetic screen was performed with eltanexor treatment implicating anti-apoptotic targets BCL2 and BCLXL, which were validated by functional testing in vitro and in vivo. These targets were tested in vivo using Sf3b1K700E conditional knock-in mice, which showed that the combination of eltanexor and venetoclax (BCL2 inhibitor) had a preferential sensitivity for SF3B1 mutant cells without excessive toxicity. In this study, we unveil the mechanisms underlying sensitization to XPO1 inhibition in SF3B1-mutant MDS and preclinically rationalize the combination of eltanexor and venetoclax for high-risk MDS.

| S-EPMC11347370 | biostudies-literature

Transposon-triggered innate immune response confers cancer resistance to the blind mole rat [array]

Project description:Transposon-triggered innate immune response confers cancer resistance to the blind mole rat [array]

| PRJNA753124 | ENA

Transposon-triggered innate immune response confers cancer resistance to the blind mole rat [seq]

Project description:Transposon-triggered innate immune response confers cancer resistance to the blind mole rat [seq]

| PRJNA751908 | ENA